Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of gene marker combination in diagnosis of endometrial cancer

A technology for endometrial cancer and biomarkers, which is applied in the determination/examination of microorganisms, biochemical equipment and methods, and instruments, etc., can solve the problems of low sensitivity, difficulty in screening patients, and inability to predict recurrence.

Inactive Publication Date: 2021-10-12
BEIJING MEDINTELL BIOMED CO LTD
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] At present, the most commonly used clinical detection markers are sugar chain antigen CA125 and human epididymis protein 4 (HE4). Among them, serum CA125 is helpful for monitoring clinical treatment effect for patients with extrauterine lesions, but for peritoneal inflammation or radiation injury CA125 may be abnormally elevated in patients with isolated vaginal metastases, but CA125 is not elevated in patients with isolated vaginal metastases, so recurrence cannot be predicted in the absence of other clinical findings. In addition, the sensitivity of CA125 and HE4 is low, and it is difficult to effectively screen patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gene marker combination in diagnosis of endometrial cancer
  • Application of gene marker combination in diagnosis of endometrial cancer
  • Application of gene marker combination in diagnosis of endometrial cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1 Screening of biomarkers related to endometrial cancer

[0073] 1. Screening method

[0074] (1) The data used for screening and preprocessing methods

[0075] In this example, the data for screening biomarkers related to endometrial cancer were downloaded from the GEO database and the TCGA database respectively, and the public gene expression data and complete clinical Note, among them, the microarray data and clinical information of the GSE17025 dataset were downloaded from the GEO database as a training set, and the sample size was endometrial cancer group: control group = 91:12; the RNA of endometrial cancer was downloaded from the TCGA database- The seq data and clinical information are used as the verification set, and the sample size is endometrial cancer group: control group = 543:35;

[0076] The fastp software double-end sequence automatic detection mode is used to process the raw data; the minimum N base number threshold is 5, the reads minimum len...

Embodiment 2

[0083] Example 2 Validation and analysis of the diagnostic efficacy of the screened biomarkers

[0084] 1. Verify the analysis method

[0085] The R package "pROC" was used to draw the receiver operating curve (ROC), and the biomarkers COL3A1, CD24, and COL3A1 that were screened in Example 1 and showed significant differential expression between the control group and the endometrial cancer group were analyzed The AUC value, sensitivity and specificity of +CD24 were used to judge its diagnostic efficacy for endometrial cancer. Among them, when evaluating and analyzing the diagnostic efficacy of single biomarkers COL3A1 and CD24 for endometrial cancer, the expression level of the gene (Log 2 expression level) for evaluation and analysis, select the point corresponding to the largest Youden index as its cutoff value, that is, the optimal division threshold is determined by the point with the largest Youden index; in the evaluation and analysis of the combined biomarker COL3A1+CD...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a gene marker combination in diagnosis of endometrial cancer. Gene markers include COL3A1 and CD24, the gene marker combination COL3A1 and CD24 can be used for diagnosis of endometrial cancer, endometrial cancer can be accurately and rapidly diagnosed with high specificity and high sensitivity, guarantee is provided for treatment as soon as possible, and the gene marker combination is suitable for large-scale popularization.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of a combination of gene markers in the diagnosis of endometrial cancer. More specifically, the combination of gene markers involved in the invention is COL3A1 and CD24. Background technique [0002] More than 90% of uterine cancers are endometrial cancers (Endometrial carcinoma, EC), which originate from the epithelium, and most of the remaining uterine cancers are mesenchymal cancers, which originate from the myometrium, and a few are endometrial stromal carcinomas, which account for about 10% of women. 7% of all cancers and a woman's lifetime risk of developing endometrial cancer is 2.5%. EC is one of the three common malignant tumors of the female reproductive system, accounting for 20%-30% of malignant tumors of the female reproductive system. In recent years, the incidence of endometrial cancer has shown a significant upward trend worldwide. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886G01N33/57484G01N33/57488G01N33/57442C12Q2600/118C12Q2600/158
Inventor 杨承刚李雨晨刘乐凯
Owner BEIJING MEDINTELL BIOMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com